Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for F...(- Restructuring costs - ...),Health

Date:8/18/2009

- Restructuring costs - Germany 14,647 - Restructuring costs - West Coast - 143 Restructuring costs - United Kingdom - 1,821 Write-off of in-process R&D - Diba acquisition - - Write-off of in-process R&D - Galpharm acquisition - - ----- ----- Adjusted operating income $70,171 $55,567 26% ======= ======= Adjusted operating income % 13.8% 11.7% Reported income from continuing operations $32,280 $32,160 0% Inventory step-up - Unico (5) - - Inventory step-up - Diba (1) - - Inventory step-up - JB Labs (2) - - Inventory step-up - Galpharm (1) - 2,072 Impairment of fixed assets (4) - - Impairment of intangible asset (3) - 6,518 Investment impairment (6) - - Loss on asset exchange (6) - - Restructuring costs - Germany (6) 14,647 - Restructuring costs - West Coast (3) - 90 Restructuring costs - United Kingdom (1) - 1,311 Write-off of in-process R&D - Diba acquisition (1) - - Write-off of in-process R&D - Galpharm acquisition (1) - - ----- -----
'/>"/>

SOURCE Perrigo Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend